Qualitative and Quantitative Heterogeniety in Acquiring Resistance to EGFR Kinase Inhibitors in Lung Cancer

被引：0

作者：

Suda, Kenichi ^{[1
]}

Murakami, Isao ^{[2
]}

Sakai, Kazuko ^{[3
]}

Mizuuchi, Hiroshi ^{[1
]}

Sato, Katsuaki ^{[1
]}

Tomizawa, Kenji ^{[1
]}

Nishio, Kazuto ^{[3
]}

Mitsudomi, Tetsuya ^{[1
]}

机构：

[1] Kinki Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Japan

[2] Higashi Hiroshima Med Ctr, Dept Resp Med, Higashihiroshima, Japan

[3] Kinki Univ, Fac Med, Dept Genome Biol, Osaka, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

T790M mutation; Molecular targeted therapy; EGFR mutation; lung adenocarcinoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL42.02

引用

页码：S256 / S257

页数：2

共 50 条

[41] Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report [J].

Fang, Liying ;

He, Jian ;

Xia, Jingwen ;

Dong, Liang ;

Zhang, Xiujuan ;

Chai, Yaqin ;

Li, Ying ;

Niu, Mengjie ;

Hang, Tianxing ;

Li, Shengqing .

ONCOLOGY LETTERS, 2017, 14 (01) :593-598

[42] Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer [J].

Jiang, Ziyang ;

Gu, Zhihan ;

Yu, Xiaomin ;

Cheng, Tao ;

Liu, Bofu .

FRONTIERS IN ONCOLOGY, 2024, 14

[43] St.Iv Lung Adenocarcinoma Treated by First-Line EGFReTyrosine Kinase Inhibitors-Survival, EGFR Mutation, Histologic Subtype [J].

Gil, T. ;

Czyzewicz, G. ;

Skoczek, M. ;

Wojcik, P. ;

Hajder, P. ;

Kolodziejczyk, B. ;

Cieslak, W. ;

Kuzdzal, J. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S878-S878

[44] The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients [J].

Wu, Shang-Gin ;

Liu, Yi-Nan ;

Tsai, Meng-Feng ;

Chang, Yih-Leong ;

Yu, Chong-Jen ;

Yang, Pan-Chyr ;

Yang, James Chih-Hsin ;

Wen, Yueh-Feng ;

Shih, Jin-Yuan .

ONCOTARGET, 2016, 7 (11) :12404-12413

[45] Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers [J].

Fukui T. ;

Mitsudomi T. .

General Thoracic and Cardiovascular Surgery, 2008, 56 (3) :97-103

[46] Expression of Mismatch Repair Proteins Associates with Survival and Response to EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients [J].

Ho, H. ;

Yeh, Y. ;

Hsieh, W. ;

Chou, T. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1926-S1926

[47] miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance [J].

Ricciuti, Biagio ;

Mecca, Carmen ;

Cenci, Matteo ;

Leonardi, Giulia Costanza ;

Perrone, Lorenzo ;

Mencaroni, Clelia ;

Crino, Lucio ;

Grignani, Francesco ;

Baglivo, Sara ;

Chiari, Rita ;

Sidoni, Angelo ;

Paglialunga, Luca ;

Curra, Maria Francesca ;

Murano, Emanuele ;

Minotti, Vincenzo ;

Metro, Giulio .

ECANCERMEDICALSCIENCE, 2015, 9

[48] Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation [J].

Barron, Feliciano ;

Cardona, Andres F. ;

Corrales, Luis ;

Ramirez-Tirado, Laura-Alejandra ;

Caballe-Perez, Enrique ;

Sanchez, Gisela ;

Flores-Estrada, Diana ;

Lucia Zatarain-Barron, Zyanya ;

Arrieta, Oscar .

JOURNAL OF THORACIC DISEASE, 2018, 10 (04) :2166-2178

[49] De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors [J].

Li, Jing-Wen ;

Cao, Shu-Hui ;

Xu, Jian-Lin ;

Zhong, Hua .

CANCER BIOLOGY & THERAPY, 2019, 20 (09) :1183-1186

[50] Emerging protein kinase inhibitors for non-small cell lung cancer [J].

Liu, Stephen V. ;

Subramaniam, Deepa ;

Cyriac, George C. ;

Abdul-Khalek, Feras J. ;

Giaccone, Giuseppe .

EXPERT OPINION ON EMERGING DRUGS, 2014, 19 (01) :51-65

← 1 2 3 4 5 →